DENALI THERAPEUTICS INC (DNLI)       31.7  -0.97 (-2.97%)

31.7  -0.97 (-2.97%)

US24823R1059 - Common Stock - After market: 31.7 0 (0%)

DENALI THERAPEUTICS INC31.7

NASDAQ:DNLI (2/3/2023, 7:00:01 PM)-0.97 (-2.97%)

After market: 31.7 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-03 2022-11-03/amc Earnings (Next) 02-27 2023-02-27/amc
Ins Owners 2% Inst Owners 67.58%
Market Cap 4.31B Shares 135.81M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 84.17
IPO 12-08 2017-12-08

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

DNLI Daily chart

Company Profile

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 413 full-time employees. The company went IPO on 2017-12-08. The firm is focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The firm clinical programs include leucine-rich repeat kinase 2 (LRRK2) inhibitor program, eukaryotic initiation factor 2 B (EIF2B) activator program, enzyme transport vehicle: iduronate 2-sulfatase (ETV:IDS) program, receptor interacting serine/threonine protein kinase 1 (RIPK1) inhibitor program and second non-CNS penetrant RIPK1 inhibitor. The firm engineers its product candidates to cross the blood-brain barrier (BBB), and act directly in the brain. Its pipeline includes approximately 15 programs that are based on its TV technology, including the lead program ETV:IDS (DNL310). Its product pipeline includes DNL151, DNL593 (PTV:PGRN), DNL126 (ETV:SGSH), DNL919 (ATV:TREM2), DNL788, DNL343, DNL758 and others.

Company Info

DENALI THERAPEUTICS INC

161 Oyster Point Blvd

South San Francisco CALIFORNIA 94080

P: 16508668548.0

CEO: Ryan J. Watts

Employees: 413

Website: https://www.denalitherapeutics.com

DNLI News

News Image11 days ago - Denali Therapeutics Inc.Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by SanofiNews Image11 days ago - Denali Therapeutics Inc.Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi

Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with multiple sclerosisDenali to receive a milestone...

News Imagea month ago - Denali Therapeutics Inc.Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage DiseasesNews Imagea month ago - Denali Therapeutics Inc.Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Four programs expected to progress in late-stage clinical studies for MPS II (Hunter syndrome), ALS, and Parkinson’s diseaseFurther validation and...

News Image2 months ago - Market News VideoDNLI Crosses Below Key Moving Average LevelNews Image2 months ago - Denali Therapeutics Inc.Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial

DNLI Twits

Here you can normally see the latest stock twits on DNLI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example